Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2024 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Regains Rights to CBX-12

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
May 25, 2023 17:01 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12

Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
April 12, 2023 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations

NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
May 15, 2019 17:01 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy

Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity

Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors Poster presentation today during AACR Annual Meeting 2019 ...
March 18, 2019 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019

NEW HAVEN, Conn., March 18, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...